Wells Fargo & Company MN grew its position in Alkermes plc (NASDAQ:ALKS - Free Report) by 36.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 94,020 shares of the company's stock after acquiring an additional 24,979 shares during the period. Wells Fargo & Company MN owned about 0.06% of Alkermes worth $2,704,000 at the end of the most recent quarter.
A number of other large investors have also added to or reduced their stakes in ALKS. CIBC Asset Management Inc grew its stake in Alkermes by 4.4% during the fourth quarter. CIBC Asset Management Inc now owns 9,155 shares of the company's stock worth $263,000 after purchasing an additional 384 shares during the period. O Shaughnessy Asset Management LLC lifted its stake in Alkermes by 3.9% in the fourth quarter. O Shaughnessy Asset Management LLC now owns 14,203 shares of the company's stock valued at $408,000 after buying an additional 532 shares during the period. Sei Investments Co. boosted its holdings in shares of Alkermes by 1.1% during the 4th quarter. Sei Investments Co. now owns 75,394 shares of the company's stock worth $2,168,000 after buying an additional 828 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Alkermes by 106.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company's stock valued at $47,000 after acquiring an additional 842 shares during the period. Finally, Venturi Wealth Management LLC bought a new position in Alkermes during the fourth quarter worth $25,000. Institutional investors own 95.21% of the company's stock.
Insider Buying and Selling
In related news, EVP Craig C. Hopkinson sold 100,918 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $32.05, for a total transaction of $3,234,421.90. Following the transaction, the executive vice president now directly owns 44,290 shares in the company, valued at $1,419,494.50. This trade represents a 69.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.40% of the stock is owned by corporate insiders.
Alkermes Stock Performance
ALKS remained flat at $28.77 during trading on Wednesday. The company had a trading volume of 2,422,948 shares, compared to its average volume of 1,759,969. The company has a 50-day simple moving average of $31.49 and a 200-day simple moving average of $30.40. Alkermes plc has a twelve month low of $22.90 and a twelve month high of $36.45. The stock has a market cap of $4.74 billion, a P/E ratio of 13.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.39.
Alkermes (NASDAQ:ALKS - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Equities analysts predict that Alkermes plc will post 1.31 earnings per share for the current year.
Analyst Ratings Changes
ALKS has been the topic of several research reports. HC Wainwright reiterated a "neutral" rating and set a $46.00 price objective on shares of Alkermes in a report on Thursday, February 13th. Royal Bank of Canada restated an "underperform" rating on shares of Alkermes in a report on Monday. UBS Group reiterated a "sector perform" rating on shares of Alkermes in a report on Monday. StockNews.com upgraded shares of Alkermes from a "buy" rating to a "strong-buy" rating in a report on Thursday, February 13th. Finally, Deutsche Bank Aktiengesellschaft lifted their price objective on shares of Alkermes from $40.00 to $52.00 and gave the company a "buy" rating in a report on Thursday, March 27th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Alkermes presently has a consensus rating of "Moderate Buy" and an average target price of $38.08.
Read Our Latest Stock Report on Alkermes
Alkermes Company Profile
(
Free Report)
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.
Recommended Stories
Before you consider Alkermes, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alkermes wasn't on the list.
While Alkermes currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
